Appetite

New YouGov Survey Results Unveiled Today During Freedom of Mobility Forum

Retrieved on: 
Wednesday, April 3, 2024
Appetite, Partnership, Freedom, Social media, Transport, YouGov, Mobility, Map

Results show that less than 10% of respondents have started making profound changes in transportation options; people in rural areas and older age groups are less interested in change

Key Points: 
  • Results show that less than 10% of respondents have started making profound changes in transportation options; people in rural areas and older age groups are less interested in change
    AMSTERDAM, April 3, 2024 – YouGov, in partnership with the Freedom of Mobility Forum, released exclusive results of a new survey measuring the appetite for change in mobility habits for respondents across five countries.
  • The results were unveiled live during the second annual Freedom of Mobility Forum and fueled the fact-based discussions with the international panel of experts and university students from three continents.
  • This is particularly notable in the USA, where more than half the respondents in rural areas said they were not ready to change anything.
  • Today’s event is facilitated by a neutral third-party and explores how planetary limits could reshape freedom of mobility from technology, business, and lifestyle perspectives.

Ike’s is Rollin' Up the Ultimate Munchie Fix: The THC Sandwich

Retrieved on: 
Tuesday, April 2, 2024
Friends, Taste, Appetite, Sandwich, Cheetos, News, Weedmaps, Love, Cheese, THC, Fast food

They're teaming up with Weedmaps – yeah, that place where you find all the best green goodies – to drop something epic: the THC Sandwich.

Key Points: 
  • They're teaming up with Weedmaps – yeah, that place where you find all the best green goodies – to drop something epic: the THC Sandwich.
  • The sandwich doesn’t have any actual THC but it's a full sesh with every bite.
  • And here’s a pro tip: Ike’s Rewards members score $4.20 off their THC Sandwich on April 20.
  • For the down-low on the THC Sandwich and all the latest Ike’s news, hit us up online or slide into the DMs at @ikesandwiches .

Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update

Retrieved on: 
Thursday, March 28, 2024
HCC, Research, Epigenomics, Toxicity, Obesity, Cell death, Growth, Burns, Gene expression, Novo Nordisk, NSCLC, AASLD, Appetite, OMEGA, DCR, Patient, Lung, Tissue, Cohort, CXCL9, CXCL10, Omega, G&A, Cancer, Messenger, Lung cancer, Human, Life expectancy, Liver regeneration, DLT, Fibrosis, Thermogenesis, Therapy, MYC, Liver, Pharmacokinetics, Hepatitis, CXCL11, LNP, Pharmaceutical industry

Research and development (R&D) expenses for the fourth quarter of 2023 were $15.5 million, compared to $26.0 million for the fourth quarter of 2022.

Key Points: 
  • Research and development (R&D) expenses for the fourth quarter of 2023 were $15.5 million, compared to $26.0 million for the fourth quarter of 2022.
  • General and administrative (G&A) expenses for the fourth quarter of 2023 were $6.2 million, compared to $5.7 million for the fourth quarter of 2022.
  • Net loss for the fourth quarter of 2023 was $20.2 million, compared to $30.8 million for the fourth quarter of 2022.
  • The decrease in net loss for 2023 compared to 2022 was primarily due to decreases in R&D expenses.

Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia

Retrieved on: 
Tuesday, March 26, 2024
Brain, Disease, Somnolence, Appetite, Partnership, Headache, Visual analogue scale, Patient, Insomnia, EDS, Anxiety, SDX, Doctor of Philosophy, Epworth Sleepiness Scale, Nausea, Clinical trial, Therapy, Safety, Narcolepsy, ESS, IHSS, Idiopathic hypersomnia, Clouding of consciousness, BFS, Food, Pharmaceutical industry

CELEBRATION, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced top-line data from its placebo-controlled, double-blind Phase 2 clinical trial (NCT05668754) evaluating the safety and tolerability of KP1077 (serdexmethylphenidate, or SDX) in patients with idiopathic hypersomnia (IH). This proof-of-concept study was not powered to demonstrate statistical significance.   The data gathered for several secondary and exploratory endpoints, including the Epworth Sleepiness Scale (ESS), Idiopathic Hypersomnia Severity Scale (IHSS) and Sleep Inertia Visual Analog Scale (SIVAS) will inform the Phase 3 study design.

Key Points: 
  • CELEBRATION, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced top-line data from its placebo-controlled, double-blind Phase 2 clinical trial ( NCT05668754 ) evaluating the safety and tolerability of KP1077 (serdexmethylphenidate, or SDX) in patients with idiopathic hypersomnia (IH).
  • The data gathered for several secondary and exploratory endpoints, including the Epworth Sleepiness Scale (ESS), Idiopathic Hypersomnia Severity Scale (IHSS) and Sleep Inertia Visual Analog Scale (SIVAS) will inform the Phase 3 study design.
  • The results from the completed Phase 2 trial provide key information for the design of a potentially pivotal Phase 3 trial of KP1077 in patients with IH.
  • The Company plans to request an end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration to seek guidance on the Phase 3 clinical trial design.

New ClearSale Report Illustrates the Staggering Impact of False Declines

Retrieved on: 
Tuesday, April 9, 2024
Technology, Finance, Security, Fintech, Professional Services, Internet, Retail, Data Management, Online Retail, ClearSale, Partner, Federal Trade Commission, Fraud, Consumer, Social media, Prevalence, Baby boomers, AI, Appetite

Global risk technology solution provider, ClearSale ( www.clear.sale ), has released a comprehensive new report that sheds light on the prevalence and consequences of false positives, commonly known as false declines.

Key Points: 
  • Global risk technology solution provider, ClearSale ( www.clear.sale ), has released a comprehensive new report that sheds light on the prevalence and consequences of false positives, commonly known as false declines.
  • The highly anticipated report, Ecommerce False Declines & Consumer Behavior, takes a deep dive into the economy of false declines, uncovering their detrimental effects on both the customer journey and a retailer’s bottom line.
  • Widespread false declines are an issue: In 2022, 25% of respondents experienced false declines, with 36% encountering multiple instances.
  • False declines are impacting retailers' revenue: Alarmingly, 65% of false declines were later validated as legitimate transactions, resulting in significant revenue loss.

Faraday Future Continues Progress in the Middle East Market with Establishment of a Middle East Sales Entity

Retrieved on: 
Tuesday, April 9, 2024
Alternative Vehicles, Fuels, Technology, EV, Electric Vehicles, Vehicle Technology, Automotive, Automotive Manufacturing, Software, Manufacturing, Internet, Artificial Intelligence, Faraday Future, FF, Multimedia, Marketing, Appetite, Retail

Faraday Future Intelligent Electric Inc. (NASDAQ: FFIE) (“Faraday Future”, “FF” or “Company”) today announced the establishment of a Middle Eastern sales entity in Dubai, signifying an important milestone in the Company’s expansion plans.

Key Points: 
  • Faraday Future Intelligent Electric Inc. (NASDAQ: FFIE) (“Faraday Future”, “FF” or “Company”) today announced the establishment of a Middle Eastern sales entity in Dubai, signifying an important milestone in the Company’s expansion plans.
  • View the full release here: https://www.businesswire.com/news/home/20240409031919/en/
    Tin Mok, Executive Director and Global Executive Vice President of User Ecosystem at Faraday Future, presents the trade license of FF's Middle East sales entity.
  • Moreover, the Company continues to engage with potential partners in the Middle East to explore opportunities, including strategic financing, business development, and sales and marketing.
  • “The establishment of a sales entity marks a pivotal moment in FF’s journey as we seek to extend our footprint into the Middle East,” said Matthias Aydt, Global CEO of FF.

STRETTO EXPANDS TREASURY AND CASH MANAGEMENT SERVICES

Retrieved on: 
Tuesday, April 9, 2024
FDIC, Risk, Organization, Utility, Appetite, Health, Bank

IRVINE, Calif., April 9, 2024 /PRNewswire/ -- Stretto, a market-leading provider of depository solutions for fiduciaries, has enhanced treasury and cash-management services for a larger range of entities in diverse industries including real estate, healthcare, utilities, consumer discretionary, industrials, and non-profit organizations. With this broadened service line, Stretto utilizes white-glove support to customize banking solutions for all types of companies with a network of FDIC-insured banks.

Key Points: 
  • With this broadened service line, Stretto utilizes white-glove support to customize banking solutions for all types of companies with a network of FDIC-insured banks.
  • "We look forward to expanding our treasury and cash-management services across a broader range of entities and organizations."
  • Leveraging Stretto Treasury & Cash Management Services, clients have access to an extensive banking network and competitive interest rates, as well as discounted activity fees and maintenance costs.
  • Clients can leverage the financial hub to accomplish important tasks such as initiating wire transfers and viewing up-to-date account summaries.

Nucific Invites You To Nuture Your Gut Microbiome and Celebrate World Health Day with Nucific Bio-X4

Retrieved on: 
Sunday, April 7, 2024
Health, Metabolism, Nutrient, Appetite, World Health Day, Probiotic, EGCG, Weight loss, Sale, Amylase, Lactobacillus, Snack, Digestion, Dietary supplement

LOS ANGELES, April 7, 2024 /PRNewswire/ -- World Health Day, observed annually on April 7th, serves as a global platform to raise awareness about pressing health issues and advocate for universal healthcare access. It aims to mobilize individuals and communities to take proactive steps towards maintaining and improving their health.

Key Points: 
  • Renowned nutritionist and Nucific® founder, Dr. Amy Lee stresses the significance of nurturing your microbiome as the cornerstone of overall health.
  • Additionally, the gut microbiome impacts various health aspects, such as mental well-being, weight management, and healthy skin.
  • Nucific's Dr. Amy Lee recommends taking care of your gut health in honor of World Health Day with supplements like Nucific BIO-X4 .
  • Nucific Bio-X4 is a groundbreaking weight support formula that contains advanced probiotics, which flood your gut with healthy slimming power.

CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy

Retrieved on: 
Saturday, April 6, 2024
Guillain–Barré syndrome, Bone marrow, Medical College of Wisconsin, Encephalopathy, Survival, Immunotherapy, BCMA, Patient, Hypotension, Mortality, B-cell maturation antigen, Edema, Periodic breathing, Associate professor, Dexamethasone, Certification, Neutropenia, Dizziness, Risk, Headache, Chills, Myelodysplastic syndrome, Coagulopathy, DPD, Johnson & Johnson, Immune system, Effect, Fatigue, Thrombocytopenia, Food, Disease, Drive, Appetite, Lymphocytopenia, JNJ, Constipation, Multiple myeloma, Acute myeloid leukemia, CRS, Death, Hypersensitivity, Cytopenia, Cytokine release syndrome, ASCO, Use, Hematology, FDA, PVD, Annual general meeting, T cell, DSM-IV codes, Incidence, Tachycardia, Bortezomib, Diarrhea, Viral, Hope, United, Cough, Daratumumab, Nausea, Society, Division, Physician, Pharmaceutical industry

HORSHAM, Pa., April 5, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.1 With this approval, CARVYKTI® becomes the first and only B-cell maturation antigen (BCMA)-targeted therapy approved for the treatment of patients with multiple myeloma as early as first relapse.

Key Points: 
  • "This milestone underscores our commitment to improve outcomes for patients and transform the treatment of multiple myeloma with CARVYKTI," said Jordan Schecter, M.D., Vice President, Disease Area Leader, Multiple Myeloma, Johnson & Johnson Innovative Medicine.
  • CARVYKTI® is a cell therapy that works by harnessing a patient's immune system, or T cells, to fight the disease.
  • Treatment requires extensive training, preparation, and certification to ensure a positive experience for patients.
  • Since initial approval in February 2022, Johnson & Johnson has made significant advances in manufacturing to rapidly scale CARVYKTI® production.

How to keep your kidneys healthy – and how to spot when things are going wrong

Retrieved on: 
Tuesday, April 9, 2024
Cooking, Blood pressure, Tea, Smartphone, Exercise, Blood, Appetite, Diabetes, Drinking water, Risk, Kidney failure, Food, Kidney disease, Nausea, Cheese, Family, Kidney, Smoking, Pharmaceutical industry

To keep your kidneys healthy there are several things you can do to help yourself.

Key Points: 
  • To keep your kidneys healthy there are several things you can do to help yourself.
  • Don’t let your kidneys dry out; make sure you drink a decent amount of fluid every day.
  • Drinking water is the best way to keep your kidneys hydrated, but any fluid such as tea or fruit-flavoured drinks are fine.
  • Smoking is bad for your kidneys, as it closes up the blood vessels in the kidneys and also increases blood pressure.